Dr. Papa on CAR T-Cell Therapy for Head and Neck Cancer

Video

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

Sophie Papa, PhD, MBBS, MRCP, King’s College London in the United Kingdom, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with head and neck cancer.

CAR T-cell therapy has become a standard of care for patients with hematologic cancers, explains Papa. It is now attempting to be used for patients with head and neck cancer. Head and neck cancer is a solid tumor that poses many challenges to CAR T-cell therapy.

In this patient population, T cells are administered intratumorally as opposed to intravenously to target the main activity in the local regional disease and reduce the risk of the T cells getting into the circulation therefore lowering the risk of toxicities, states Papa.

Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
© 2025 MJH Life Sciences

All rights reserved.